Alanine Aminotransferase (ALT) Continuous Monitoring Assay: Principle, Procedure, and Clinical Appli

The alanine aminotransferase (ALT) continuous monitoring assay is the IFCC-recommended kinetic method for measuring ALT catalytic activity in serum or plasma, based on the rate of NADH oxidation monitored continuously at 340 nm. Coupled with the lactate dehydrogenase indicator reaction, this technique delivers rapid, precise, and highly specific quantification of hepatocellular injury on automated chemistry analyzers. This article reviews the assay principle, reagents, step-by-step procedure, calculation, quality control, and clinical applications of the ALT continuous monitoring determination.

Technical Overview

Alanine aminotransferase (ALT; EC 2.6.1.2), formerly known as serum glutamate pyruvate transaminase (SGPT), is a pyridoxal phosphate-dependent enzyme that catalyzes the reversible transfer of an amino group from L-alanine to 2-oxoglutarate, yielding pyruvate and L-glutamate. Because ALT is concentrated predominantly in the hepatocyte cytoplasm, its catalytic activity in blood is widely regarded as the most liver-specific marker of hepatocellular damage.

The continuous monitoring (kinetic) determination is the internationally standardized reference procedure recommended by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC). In this method, the pyruvate formed by ALT is immediately reduced to lactate by exogenous lactate dehydrogenase (LDH) with concurrent oxidation of NADH to NAD+. The decrease in absorbance at 340 nm, recorded continuously over a defined reading window at 37 °C, is directly proportional to the ALT activity in the specimen.

• Kinetic ultraviolet measurement at 340 nm, with secondary wavelengths of 334 nm and 365 nm
• Coupled NADH/LDH indicator reaction providing high analytical specificity
• IFCC-standardized conditions (37 °C, defined substrate concentrations, pyridoxal-5-phosphate activation)
• Full compatibility with automated biochemistry analyzers and open-system reagent kits
• Traceability of results to the international reference material ERM-AD454/IFCC

Compared with legacy endpoint techniques such as the dinitrophenylhydrazine colorimetric method, the continuous monitoring assay offers superior precision, a wider linear range, a shorter turnaround time, and complete automation capability, and it has therefore become the routine method in clinical laboratories worldwide.

Testing Samples

Serum

Serum is the preferred specimen. Collect venous blood into a plain or separator-gel tube, allow complete clotting for 20 to 30 minutes at room temperature, and centrifuge at approximately 1,500 to 2,000 × g for 10 minutes. Each sample should be visually inspected for hemolysis, icterus, and lipemia before analysis.

Plasma

Lithium heparin plasma is an acceptable alternative and permits faster turnaround. EDTA plasma may be used only where the reagent manufacturer has verified suitability for the method. Anticoagulants such as citrate, oxalate, and fluoride introduce dilution or chemical interference and should be avoided.

Specimen Handling, Stability, and Interferences

ALT is a relatively stable enzyme: activity is generally maintained for at least 24 hours at 20 to 25 °C, for 3 to 7 days at 2 to 8 °C, and for several months at −20 °C or below, provided the samples are tightly sealed and repeated freeze-thaw cycles are avoided. The principal sources of interference are:

• Hemolysis: released erythrocyte lactate dehydrogenase and adenine nucleotides accelerate NADH oxidation, causing positive bias, while hemoglobin adds direct spectral interference at 340 nm.
• Lipemia: turbidity scatters light and distorts the absorbance slope; ultracentrifugation or sample blanking may be required.
• Icterus: high bilirubin concentrations can bias readings; bichromatic measurement or a sample blank is recommended.
• Endogenous keto acids: elevated pyruvate prolongs the lag phase and must be depleted during pre-incubation.
• Certain drugs and metabolites that affect NADH-dependent side reactions in the specimen.

Testing Items

The measurand is the catalytic activity concentration of alanine aminotransferase in serum or plasma, expressed as units per liter (U/L) at 37 °C, where one unit equals one micromole of substrate converted per minute. SI reporting in microkatals per liter is also acceptable (1 U/L = 0.0167 μkat/L).

Typical adult reference intervals with IFCC-standardized, pyridoxal-5-phosphate-supplemented reagents at 37 °C are approximately 9 to 50 U/L for men and 9 to 35 U/L for women, although each laboratory must verify its own limits. Mild elevations of up to five times the upper reference limit suggest fatty liver disease, chronic hepatitis, or alcohol-related injury, whereas values exceeding ten times the upper limit strongly indicate acute hepatocellular damage such as viral or toxic hepatitis. Results should always be interpreted together with AST, ALP, GGT, and bilirubin.

Testing Methods

Assay Principle

The determination is a two-step coupled enzymatic reaction system:

L-alanine + 2-oxoglutarate → pyruvate + L-glutamate (ALT, primary reaction)

Pyruvate + NADH + H+ → lactate + NAD+ (LDH, indicator reaction)

The rate of NADH consumption, monitored as the decrease in absorbance at 340 nm, is directly proportional to ALT activity. The molar absorptivity of NADH is 6.3 L·mmol⁻¹·cm⁻¹ in the current IFCC formulation (6.22 in classical methods), and measurements are performed at 37 °C with a 1 cm light path.

Reagents and Instrumentation

A representative IFCC-compatible reagent system comprises two components:

• Reagent 1 (pre-incubation reagent): Tris buffer 100 mmol/L at pH 7.15 (37 °C); L-alanine 500 mmol/L; NADH 0.18 mmol/L; lactate dehydrogenase at least 1,700 U/L; pyridoxal-5-phosphate 0.1 mmol/L.
• Reagent 2 (start reagent): 2-oxoglutarate (α-ketoglutarate) 15 mmol/L.

The required instrumentation is a UV-capable spectrophotometer or automated chemistry analyzer with thermostatted cuvette positions controlled to 37 ± 0.1 °C, a 340 nm filter or monochromator setting (mercury line alternatives of 334 nm and 365 nm may be used with adjusted calculation factors), and timing accuracy sufficient for interval absorbance readings.

Step-by-Step Procedure

• Equilibrate reagents and specimens to 37 °C and verify that the reagent blank absorbance at 340 nm meets the kit specification, typically at least 1.0, confirming adequate NADH concentration.
• Pipette the sample and Reagent 1 into the cuvette and mix gently; typical manual protocols use 100 μL of sample, while automated analyzers use 10 to 25 μL.
• Pre-incubate for 3 to 5 minutes so that endogenous pyruvate and other keto acids are depleted by LDH and pyridoxal-5-phosphate fully saturates the ALT apoenzyme.
• Add Reagent 2 to initiate the primary reaction, mix without foaming, and start timing immediately.
• Observe a lag phase of 60 to 90 seconds to allow the coupled reactions to reach steady state.
• Record absorbance at 340 nm at fixed intervals for 1 to 3 minutes and compute the mean change in absorbance per minute (ΔA/min).
• If the reaction rate exceeds the validated linear range, dilute the specimen with isotonic saline, repeat the measurement, and multiply the result by the dilution factor.

Calculation of ALT Activity

ALT activity is calculated from the measured absorbance slope using the following relationship:

ALT (U/L) = (ΔA/min × Vt × 1000) / (ε × b × Vs)

where Vt is the total reaction volume in mL, Vs is the sample volume in mL, ε is the molar absorptivity of NADH, and b is the light path in cm. For a typical total-to-sample volume ratio of 11:1, the assay factor is approximately 1,746 to 1,768 depending on the absorptivity value used; the manufacturer provides the exact factor in the package insert. Any drift from spontaneous NADH oxidation in the reagent blank is subtracted before calculation.

Calibration, Linearity, and Quality Control

Because the calculation is factor-based and anchored to the physicochemical constant of NADH, calibration is commonly performed with a single calibrator traceable to ERM-AD454/IFCC or by direct application of the calculation factor. Key analytical performance requirements include:

• Linearity verified to at least 400 to 600 U/L, depending on the reagent system, with dilution and repeat testing above the limit.
• Between-run imprecision typically within 3 to 5% CV across the measuring range.
• Analysis of two levels of internal quality control material (normal and elevated) in every run, evaluated with Westgard multirules.
• Verification of cuvette temperature, wavelength accuracy, and pipetting precision, together with regular participation in external quality assessment schemes.

Applications

The ALT continuous monitoring assay is one of the most frequently performed enzyme determinations in clinical chemistry, supporting patient care, public health, and industry:

• Detection and monitoring of liver diseases, including acute viral hepatitis, chronic hepatitis B and C, autoimmune hepatitis, non-alcoholic fatty liver disease, alcoholic liver disease, cirrhosis, and ischemic or toxic hepatopathy.
• Surveillance for drug-induced liver injury during therapy with antitubercular agents, high-dose acetaminophen, statins, methotrexate, anticonvulsants, and cytotoxic chemotherapy.
• Blood donor screening and transfusion safety programs as a surrogate marker of viral hepatitis.
• Pharmaceutical clinical trials, where ALT is a core safety laboratory parameter under international regulatory guidance.
• Occupational health surveillance of workers exposed to hepatotoxic solvents and industrial chemicals.
• General health examinations, pre-operative assessment, and insurance medical underwriting.
• Veterinary diagnostics and biomedical research into hepatic metabolism and toxicology, using appropriately validated species-specific reference intervals.

Elevated results guide further investigation such as viral serology, autoimmune panels, and hepatic imaging, while serial measurements are used to track disease progression, therapeutic response, and recovery.

FAQ

Why is the assay monitored at 340 nm?

NADH has a strong absorption maximum at 340 nm, whereas NAD+ does not absorb at this wavelength. The linear decrease in absorbance therefore directly reflects the rate of the coupled reaction and, consequently, the ALT activity present in the sample.

Why is a pre-incubation step necessary?

Serum contains endogenous pyruvate and other keto acids that would otherwise consume NADH and falsely elevate the result. Pre-incubation allows the LDH in the reagent to clear these substrates and allows pyridoxal-5-phosphate to fully activate ALT before the primary reaction is initiated with 2-oxoglutarate.

What is the role of pyridoxal-5-phosphate?

Pyridoxal-5-phosphate is the coenzyme of ALT. Supplementation ensures that any apo-enzyme present in the specimen, particularly in patients with vitamin B6 deficiency or advanced liver disease, is fully saturated, which improves accuracy and inter-laboratory comparability.

How is the final result obtained?

The analyzer measures the change in absorbance per minute at 340 nm, subtracts any reagent blank drift, and multiplies the slope by a factor derived from the reaction volume, sample volume, and molar absorptivity of NADH, reporting the activity in U/L at 37 °C.

Which conditions elevate serum ALT?

Marked elevations occur in acute viral hepatitis, toxic or ischemic hepatocellular injury, and fulminant hepatic failure. Mild to moderate elevations are typical of fatty liver disease, chronic viral hepatitis, alcohol-related liver disease, and medication effects. Strenuous exercise and skeletal muscle injury can also raise ALT modestly.

How does ALT differ from AST?

ALT is located mainly in the liver cytosol and is more liver-specific, whereas AST is also abundant in heart, skeletal muscle, kidney, and brain. The AST/ALT ratio, known as the De Ritis ratio, adds diagnostic value: a ratio above 2 suggests alcoholic liver disease, while ratios below 1 are common in viral hepatitis and non-alcoholic fatty liver disease.

Can hemolyzed samples be analyzed?

Hemolyzed specimens should generally be rejected or clearly flagged, because released LDH and free hemoglobin cause positive interference at 340 nm. Whenever the hemolysis index exceeds the manufacturer's acceptance limit, a newly collected specimen is recommended.